We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+10.58%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$604M
AUM Growth
-$93M
(-13%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-22.99%
Top 10 Holdings %
Top 10 Hldgs %
48.64%
Holding
92
New
16
Increased
10
Reduced
22
Closed
33
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
1.4
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
1.2
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$29.3M |
| 2 |
Globus Medical
GMED
|
+$25.7M |
| 3 |
Cencora
COR
|
+$21M |
| 4 |
Cigna
CI
|
+$16.3M |
| 5 |
Viatris
VTRS
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$27.8M |
| 2 |
Corcept Therapeutics
CORT
|
+$27.2M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$27.1M |
| 4 |
LivaNova
LIVN
|
+$26.8M |
| 5 |
Embecta
EMBC
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.2% |
| 2 | Industrials | 6.36% |
| 3 | Miscellaneous | 3.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Anteris Technologies
AVR
$640M
| $54.6M | 9.04% |
5,545,984
+163,019
| +3% | +$1.24M |
2024 Q4
6 quarters
|
|
|
2
Cencora
COR
$62.7B
| $49.1M | 8.13% |
173,588
+72,694
| +72% | +$21M |
2025 Q4
2 quarters
|
|
3
Maximus
MMS
$3.13B
| $38.5M | 6.36% |
715,267
-53,558
| -7% | -$3.34M |
2024 Q3
7 quarters
|
|
|
4
Allogene Therapeutics
ALLO
$463M
| $27.7M | 4.59% |
+13,323,431
| New | +$29.3M |
2026 Q2
0 quarters
|
|
|
5
Globus Medical
GMED
$10.2B
| $23.8M | 3.95% |
+301,816
| New | +$25.7M |
2026 Q2
0 quarters
|
|
6
GSK
GSK
$93.5B
| $22.9M | 3.79% |
436,700
+50,821
| +13% | +$2.69M |
2026 Q1
1 quarter
|
|
7
Tyra Biosciences
TYRA
$1.31B
| $22.2M | 3.68% |
695,315
+89,876
| +15% | +$2.97M |
2024 Q1
9 quarters
|
|
8
Waystar Holding Corp
WAY
$5.19B
| $19M | 3.15% |
925,834
-716,402
| -44% | -$15.1M |
2025 Q4
2 quarters
|
|
9
PUT
SELLAS Life Sciences
SLS
$2.41B
| $18.2M | 3.01% |
+1,230,700
| New | +$8.5M |
2026 Q2
0 quarters
|
|
10
IDEAYA Biosciences
IDYA
$3.42B
| $17.9M | 2.96% |
+480,383
| New | +$14.7M |
2026 Q2
0 quarters
|
|
11
Oruka Therapeutics
ORKA
$5.26B
| $16.9M | 2.79% |
177,118
+44,622
| +34% | +$2.97M |
2025 Q4
2 quarters
|
|
|
12
Cigna
CI
$74.3B
| $15.9M | 2.63% |
+57,750
| New | +$16.3M |
2026 Q2
0 quarters
|
|
13
Sanofi
SNY
$95B
| $15.5M | 2.57% |
364,200
+124,529
| +52% | +$5.56M |
2025 Q2
4 quarters
|
|
|
14
Icon
ICLR
$12.4B
| $15.3M | 2.54% |
88,186
-218,172
| -71% | -$27.8M |
2025 Q4
2 quarters
|
|
|
15
Viatris
VTRS
$20B
| $15.2M | 2.51% |
+954,299
| New | +$14.8M |
2026 Q2
0 quarters
|
|
16
DELISTED
Cross Country Healthcare
CCRN
| $14.5M | 2.4% |
1,098,393
| – | – |
2025 Q4
2 quarters
|
|
17
Rapport Therapeutics
RAPP
$1.4B
| $12.8M | 2.12% |
307,657
-59,152
| -16% | -$2.17M |
2025 Q3
3 quarters
|
|
18
Abbott
ABT
$175B
| $11.7M | 1.93% |
128,656
-57,918
| -31% | -$5.29M |
2026 Q1
1 quarter
|
|
19
Celcuity
CELC
$3.16B
| $11.5M | 1.9% |
110,022
-83,821
| -43% | -$9.67M |
2025 Q3
3 quarters
|
|
20
Zimmer Biomet
ZBH
$17.7B
| $11.3M | 1.87% |
131,445
+68,832
| +110% | +$6.04M |
2025 Q4
2 quarters
|
|
21
Regeneron Pharmaceuticals
REGN
$76.7B
| $11.2M | 1.86% |
+18,000
| New | +$12.3M |
2026 Q2
0 quarters
|
|
22
Bristol-Myers Squibb
BMY
$115B
| $11.1M | 1.85% |
+193,500
| New | +$11.1M |
2026 Q2
0 quarters
|
|
23
Medtronic
MDT
$117B
| $11.1M | 1.84% |
+142,500
| New | +$11.5M |
2026 Q2
0 quarters
|
|
24
Vir Biotechnology
VIR
$1.87B
| $11M | 1.81% |
1,075,274
-423,346
| -28% | -$4.03M |
2024 Q4
6 quarters
|
|
25
Senseonics Holdings Inc
SENS
$480M
| $9.05M | 1.5% |
1,592,692
+1,476,908
| +1,276% | +$9.46M |
2025 Q2
4 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sio Capital Management held 92 positions worth $604M, down 13% from $697M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sio Capital Management withdrew a net $139M in Q2 2026, closing 33 positions and reducing 22 holdings. Its most notable exit was Corcept Therapeutics, an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, Sio Capital Management opened a new position in Allogene Therapeutics worth $27.7M.
- Sio Capital Management's largest Q2 2026 buy was Allogene Therapeutics: 13,323,431 shares worth $27.7M.
- Sio Capital Management added most to Cencora in Q2 2026, an estimated $21M increase.
- Sio Capital Management's biggest Q2 2026 reduction was Icon, cutting an estimated $27.8M.
- Sio Capital Management fully exited Corcept Therapeutics in Q2 2026, selling an estimated $27.2M.
- Sio Capital Management's ten largest holdings make up 49% of its $604M portfolio in Q2 2026.
- Sio Capital Management opened 16 new positions and closed 33 in Q2 2026.
- Sio Capital Management's portfolio value fell 13% quarter-over-quarter to $604M.
Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.